'Leaving no stones unturned': up to 10 years results on the effectiveness, tolerability and metabolic safety of dolutegravir+lamivudine (DTG+3TC) as a switch regimen in the ODOACRE cohort. (academic.oup.com)

Authors: Ciccullo A … Di Giambenedetto S Journal: Journal of Antimicrobial Chemotherapy Published: 2026-05-05 DOI: https://doi.org/10.1093/jac/dkag172